Human papillomavirus in the era of highly active antiretroviral therapy for human immunodeficiency virus: an immune reconstitution-associated disease?

被引:21
作者
Meys, R. [1 ]
Gotch, F. M. [2 ]
Bunker, C. B. [1 ]
机构
[1] Univ London Imperial Coll Sci Technol & Med, Chelsea & Westminster Hosp, Dept Dermatol, London SW10 9NH, England
[2] Univ London Imperial Coll Sci Technol & Med, Chelsea & Westminster Hosp, Dept Immunol, London SW10 9NH, England
关键词
HAART; HIV; HPV; immune reconstitution disease; IRD; INFLAMMATORY SYNDROME; CUTANEOUS WARTS; INTRAEPITHELIAL NEOPLASIA; RESTORATION DISEASE; HPV INFECTIONS; RISK-FACTORS; HIV; MANIFESTATIONS; PREVALENCE; IMPACT;
D O I
10.1111/j.1365-2133.2009.09365.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
P>Human immunodeficiency virus (HIV)-related cutaneous and anogenital disease in the highly active antiretroviral therapy (HAART) era presents challenging problems for dermatologists. Immune reconstitution-associated diseases (IRADs) are common and important consequences of HAART. Dermatologists should be aware of the cutaneous manifestations of IRAD. The prevalence of clinical human papillomavirus (HPV)-related disease is increased in HIV and does not appear to be diminished by HAART. Many patients on HAART are dogged by persistent cutaneous warts. Anogenital precancer is also common in HIV and may be burgeoning with HAART. Clinicians should be aware of the increased risk of cervical, penile and vulval/vaginal cancers in treated and untreated patients with HIV. The increase in HPV infection in HIV-infected individuals may be, at least partly, due to increased exposure to diverse HPV types, particularly high-risk types that might be able to persist for longer in anogenital regions. Alternatively, persistent/emergent HPV disease in HIV infection might represent persistent or modulated immunodysregulation after HAART and be viewed as a form of IRAD. The immunopathogenesis of HPV IRAD is fascinating and possibly determined by host genotype.
引用
收藏
页码:6 / 11
页数:6
相关论文
共 52 条
  • [1] [Anonymous], 2007, IARC monographs on the evaluation of carcinogenic risks to humans, P421
  • [2] Barzegar C, 1998, BRIT J DERMATOL, V139, P122
  • [3] EPIDERMODYSPLASIA VERRUCIFORMIS-ASSOCIATED PAPILLOMAVIRUS INFECTION COMPLICATING HUMAN-IMMUNODEFICIENCY-VIRUS DISEASE
    BERGER, TG
    SAWCHUK, WS
    LEONARDI, C
    LANGENBERG, A
    TAPPERO, J
    LEBOIT, PE
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 1991, 124 (01) : 79 - 83
  • [4] BUNKER CB, 2009, ROOKS TXB DERMATOLOG
  • [5] The impact of highly active antiretroviral therapy and immunodeficiency on human papillomavirus infection of the oral cavity of human immunodeficiency virus-seropositive adults
    Cameron, JE
    Mercante, D
    O'Brien, M
    Gaffga, AM
    Leigh, JE
    Fidel, PL
    Hagensee, ME
    [J]. SEXUALLY TRANSMITTED DISEASES, 2005, 32 (11) : 703 - 709
  • [6] Antiretroviral therapy for HIV infection in 1996 - Recommendations of an international panel
    Carpenter, CCJ
    Fischl, MA
    Hammer, SM
    Hirsch, MS
    Jacobsen, DM
    Katzenstein, DA
    Montaner, JSG
    Richman, DD
    Saag, MS
    Schooley, RT
    Thompson, MA
    Vella, S
    Yeni, PG
    Volberding, PA
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (02): : 146 - 154
  • [7] Unusual HPV types in cutaneous warts in association with immunological deficiency
    Cavalcanti, SMB
    Deus, FCC
    Oliveira, LHS
    [J]. MEMORIAS DO INSTITUTO OSWALDO CRUZ, 1998, 93 (04): : 433 - 434
  • [8] Natural history and clinical management of anal human papillomavirus disease in men and women infected with human immunodeficiency
    Chin-Hong, PV
    Palefsky, JM
    [J]. CLINICAL INFECTIOUS DISEASES, 2002, 35 (09) : 1127 - 1134
  • [9] CHOREMIS CB, 1955, AM REV TUBERC PULM, V72, P527
  • [10] Clinical indicators of immune restoration following highly active antiretroviral therapy
    Cooney, EL
    [J]. CLINICAL INFECTIOUS DISEASES, 2002, 34 (02) : 224 - 233